stuitligging, uitwendige versie, uterus relaxatie, atosiban, oxytocine antagonist, fenoterol, betamimetica. UK: breech presentation, external cephalic version, uterine relaxation, atosiban, oxytocine antagonist, fenoterol, betamimetics.
Conditions
Interventions
Comparison of a bolus atosiban 6,75 mg iv compared to a bolus 40 micrograms iv 15 minutes before ECV.
Sponsors
Academic Medical Center (AMC)
Eligibility
Inclusion criteria
Inclusion criteria: 1. Pregnant women (from 18 years of age) with a live singleton fetus in breech presentation; 2. 32 weeks of gestation and onwards.
Exclusion criteria
Exclusion criteria: 1. Contraindications to labour or vaginal birth; 2. Any contraindication to ECV; 3. Contra-indications for fenoterol or atosiban.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Succesfull version; number of cephalic presentations half an hour after the procedure; 2. Fetal presentation at delivery. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Mode of delivery; vaginal delivery (spontaneous or instrumental), CS (prelabor or during labor); 2. Complications of ECV; persistent non-reassuring fetal CTG after ECV, umbilical cord prolapse, (P)PROM, placental abruption, emergency delivery, fetal death; 3. Adverse events due to atosiban or fenoterol; chest pain, nausea, vomitting, headaches, flushing, dizziness, hypotension (associated with fainting or CTG abnormalities), tachycardia resulting in palpitations, local reaction of the skin on injection of the medication, anaphylactic shock, cessation of treatment due to side effects. | — |
Contacts
Public ContactF. Vlemmix
Academic Medical Center (AMC) Dept Gynaecology & Obstetrics, H4-140.1 Meibergdreef 8
Outcome results
None listed